Acta Scientific Otolaryngology (ASOL) (ISSN: 2582-5550)

Research Article Volume 3 Issue 7

Covid 19 Associated Mucormycosis: An Epidemic

Kanishk Mehta1*, Priti Agarwal2 and Swati Jain3

1Associate Professor, Department of Otorhinolaryngology and Head Neck Surgery, American International Institute of Medical Sciences, Udaipur, Rajasthan, India
2Professor and Head, Department of Pathology, American International Institute of Medical Sciences, Udaipur, Rajasthan, India
3Assistant Professor, Department of Ophthalmology, American International Institute of Medical Sciences, Udaipur, Rajasthan, India

*Corresponding Author: Kanishk Mehta, Associate Professor, Department of Otorhinolaryngology and Head Neck Surgery, American International Institute of Medical Sciences, Udaipur, Rajasthan, India.

Received: May 24, 2021; Published: June 10, 2021

Abstract

Patients with Coronavirus disease (COVID-19) are commonly treated with broad spectrum antibiotics, glucocorticoids and/or immune modulators. This has led to development/exacerbation of opportunistic fungal infections. Mucormycosis is one such disease that complicates the course of severe COVID-19. Here we present a study of 15 patients and their epidemiology who were diagnosed with Covid19 Associated Mucormycosis (CAM) at our institute - the highest number of cases in literature.

Keywords: Mucormycosis; COVID19; Immunosuppression

References

  1. Mehta S and Pandey A. “Rhino-Orbital Mucormycosis Associated with COVID 19”. Cureus9 (2020): e10726.
  2. Chen N., et al. “Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study”. Lancet 395 (2020): 507-513.
  3. Rawson TM., et al. “Bacterial and fungal co-infection in individuals with coronavirus: a rapid review to support COVID-19 antimicrobial prescribing”. Clinical Infectious Diseases (2020).
  4. Clinical management protocol for COVID-19 (2020).
  5. RECOVERY Collaborative Group; Peter Horby., et al. “Dexamethasone in hospitalized patients with Covid-19 - preliminary report. The RECOVERY Collaborative Group”. The New England Journal of Medicine (2020).
  6. COVID-19 Treatment Guidelines Panel. Coronavirus disease 2019 (COVID-19) treatment guidelines. National Institutes of Health (2020).
  7. Gangneux JP., et al. “Invasive fungal diseases during COVID-19: we should be prepared”. Journal of Medical Mycology 30 (2020): 100971.
  8. Singh A., et al. “Mucormycosis in COVID-19: A systematic review of cases reported worldwide and in India” (2021).
  9. AM Sugar. “Mucormycosis”. Clinical Infectious Disease 14 (1992): S126-S129.

Citation

Citation: Kanishk Mehta., et al. “Covid 19 Associated Mucormycosis: An Epidemic".Acta Scientific Otolaryngology 3.7 (2020): 27-31.

Copyright

Copyright: © 2020 Kanishk Mehta., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.




Metrics

Acceptance rate34%
Acceptance to publication20-30 days
Impact Factor0.871

Indexed In








News and Events


  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is May 25, 2022.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of “Best Article of the Issue”.
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.
  • Contact US